Modality
Degrader
MOA
CD3xCD20
Target
CGRP
Pathway
PD-1/PD-L1
CMLCKD
Development Pipeline
Preclinical
~Oct 2013
→ ~Jan 2015
Phase 1
~Apr 2015
→ ~Jul 2016
Phase 2
~Oct 2016
→ ~Jan 2018
Phase 3
~Apr 2018
→ ~Jul 2019
NDA/BLA
Oct 2019
→ Nov 2031
NDA/BLACurrent
NCT04756354
1,728 pts·CKD
2019-10→2031-11·Active
1,728 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-11-045.6y awayPh3 Readout· CKD
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
NDA/BLA
Active
Catalysts
Ph3 Readout
2031-11-04 · 5.6y away
CKD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04756354 | NDA/BLA | CKD | Active | 1728 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP |